1-20 of 78
Jürgen Krauter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Myelodysplasia-Related Gene Mutations for NGS-Based MRD Assessment in Acute Myeloid Leukemia

Maximilian Bader, Arba Mahmuti, Jannika Leßmann, Henri C Hupe, Razif Gabdoulline, Martin Wichmann, Letizia Venturini, Michael Stadler, Wolfram Puppe, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Matthias Eder, Arnold Ganser, Felicitas Thol, Michael Heuser, Rabea Mecklenbrauck
Journal: Blood
Blood (2023) 142 (Supplement 1): 2944.
https://doi.org/10.1182/blood-2023-181637
Published: 2023
Journal Articles

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Rabea Mecklenbrauck, Nora Borchert, Piroska Klement, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas Thol, Michael Heuser
Journal: Blood
Blood (2023) 142 (Supplement 1): 817.
https://doi.org/10.1182/blood-2023-179412
Published: 2023
Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo, Jan Novak, Gabriela Rodriguez Macias, Stephan Metzelder, Arpad Illes, Agnes Nagy, Jiří Mayer, Montserrat Arnan Sangerman, Mary-Margaret Keating, Jürgen Krauter, Monia Lunghi, Nicola Fracchiolla, Uwe Platzbecker, Valeria Santini, Danna Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 1538.
https://doi.org/10.1182/blood-2023-173092
Published: 2023
Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W.M. Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Mohammad Wattad, Katharina Götze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Jürgen Krauter, Uwe M. Martens, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp-Schwoerer, Lars Bullinger, Felicitas R. Thol, Michael Heuser, Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Döhner, Arnold Ganser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2010–2013.
https://doi.org/10.1182/blood-2022-166084
Published: 2022
Journal Articles

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Rabea Mecklenbrauck, Nora Borchert, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Piroska Klement, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Andreas Voss, Michael Lübbert, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas R. Thol, Michael Heuser
Journal: Blood
Blood (2022) 140 (Supplement 1): 6254–6255.
https://doi.org/10.1182/blood-2022-162725
Published: 2022
Journal Articles

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J. Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novák, Wieslaw W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M. Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen W. L. Yee, Jean-Pierre J. Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner
Journal: Blood
Blood (2022) 140 (3): 285–289.
https://doi.org/10.1182/blood.2022015832
Published: 2022
Includes: Supplemental data
Journal Articles

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Luca Fischer, Linmiao Jiang, Joerg Bittenbring, Kai Hübel, Christian Schmidt, Johannes Duell, Bernd Metzner, Jürgen Krauter, Bertram Glass, Andreas Hüttmann, Kerstin Schaefer-Eckart, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Martin H. Dreyling, Eva Hoster
Journal: Blood
Blood (2021) 138 (Supplement 1): 3551.
https://doi.org/10.1182/blood-2021-148074
Published: 2021
Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Stephane De Botton, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Jordi Esteve, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Olivier Legrand, Pierre Peterlin, Montserrat Arnan Sangerman, William G. Blum, Daniela Cilloni, Devendra Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin Watts, Jay Yang, Zihao Xin, Alex Sedkov, Sylvie Guichard, Jennifer Sweeney, Christophe Marzac, Jorge E. Cortes, Pierre Fenaux
Journal: Blood
Blood (2021) 138 (Supplement 1): 2351.
https://doi.org/10.1182/blood-2021-144912
Published: 2021
Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Crysandt, Edgar Jost, Felicitas Thol, Michael Heuser, Katharina S. Goetze, Richard F. Schlenk, Helmut R. Salih, Marcus M. Schittenhelm, Gerhard Heil, Carsten Schwaenen, Carsten Müller-Tidow, Wolfram Brugger, Andrea Kündgen, Ulrich Germing, Maike de Wit, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Jürgen Krauter, Gesine Bug, Annette M. May, Ralph Wäsch, Justus Duyster, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Björn Hackanson, Michael Lübbert
Journal: Blood
Blood (2021) 138 (Supplement 1): 2380.
https://doi.org/10.1182/blood-2021-146468
Published: 2021
Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Jacqueline J Cloos, Pau Montesinos, Walter Fiedler, Rouven Müller, Jürgen Krauter, Simona Sica, Jörg Westermann, Maaike E Heidinga, Lok Lam Ngai, Yvonne J.M Oussoren-Brockhoff, Hartmut Döhner, Mark Levis, Gert J. Ossenkoppele, Richard M. Stone, Giedre Koenen, Bourras-Rezki Bengoudifa, Yuan Cheng, Thierry Medts, Valerie Heidinger, Carolin Sachs, Jorge Sierra
Journal: Blood
Blood (2021) 138 (Supplement 1): 1303.
https://doi.org/10.1182/blood-2021-148129
Published: 2021
Journal Articles

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Clinical Trials & Observations
Silke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönke, Frauke Theis, Frank G. Rücker, Maria-Veronica Teleanu, Ekaterina Panina, Nikolaus Jahn, Julia Herzig, Lena Kubanek, Anika Schrade, Gudrun Göhring, Walter Fiedler, Thomas Kindler, Thomas Schroeder, Karin T. Mayer, Michael Lübbert, Mohammed Wattad, Katharina S. Götze, Heinz A. Horst, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Martin Bentz, Jürgen Krauter, Lars Bullinger, Julia Krzykalla, Axel Benner, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood
Blood (2020) 136 (26): 3041–3050.
https://doi.org/10.1182/blood.2020005998
Published: 2020
Includes: Supplemental data
Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Michael Luebbert, MD PhD, Olga Grishina, Claudia Schmoor, Martina Crysandt, Edgar Jost, Felicitas Thol, Michael Heuser, Katharina S. Götze, Richard F. Schlenk, Konstanze Döhner, Helmut R. Salih, Marcus M. Schittenhelm, Gerhard Heil, Carsten Schwaenen, Carsten Mueller-Tidow, MD, Wolfram Brugger, Andrea Kündgen, Ulrich Germing, Maike de Wit, Stephan Kremers, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Professor Dr, Jürgen Krauter, Gesine Bug, Ralph Wäsch, Heiko Becker, Christoph Rummelt, Annette M. May, Justus Duyster, Arnold Ganser, Björn Hackanson, Hartmut Döhner
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-140664
Published: 2020
Journal Articles

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Verena I Gaidzik, MD, Verena Mayr-Benedikter, Daniela Weber, MSc, Anika Schrade, PhD, Jürgen Krauter, Juliane S. Walz, MD, Holger Hebart, MD, Beate S. Schultheis, MD, Nadezda Basara, MD, Elisabeth Dietl, MD, Silke Kapp-Schwoerer, MD, Michaela Feuring-Buske, MD, Felicitas Thol, Michael Heuser, Stefan Faderl, MD, Anthony J. Wagner, Maral Saadati, Julia Krzykalla, PhD, Axel Benner, Arnold Ganser, Konstanze Döhner, Peter Paschka, MD, Hartmut Döhner
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-138738
Published: 2020
Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Clinical Trials & Observations
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Maria Teresa Voso, Tiziana Ottone, Josep F. Nomdedeu, Sumithra J. Mandrekar, Rebecca B. Klisovic, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Celine Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield
Journal: Blood
Blood (2020) 135 (5): 371–380.
https://doi.org/10.1182/blood.2019002697
Published: 2020
Includes: Supplemental data
Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 177.
https://doi.org/10.1182/blood-2019-124050
Published: 2019
Journal Articles

Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation

Felicitas Thol, MD, Bennet Heida, Konstatin Buettner, Clara Wienecke, Katrin Teich, Carolin Funke, Brandes Maximilian, Piroska Klement, Alessandro Liebich, Johannes Schiller, Martin Wichmann, Blerina Neziri, Anuhar Chaturvedi, PhD, Arnold Kloos, PhD, Verena I. Gaidzik, MD, Peter Paschka, MD, Lars Bullinger, Walter Fiedler, MD, Albert Heim, MD, Jürgen Krauter, MD, Konstanze Döhner, Hartmut Döhner, MD, Arnold Ganser, MD, Michael Stadler, MD PhD, Lothar Hambach, MD, Razif Gabdoulline, Michael Heuser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 184.
https://doi.org/10.1182/blood-2019-125532
Published: 2019
Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3916.
https://doi.org/10.1182/blood-2019-124034
Published: 2019
Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Frank G. Rücker, MD, Mridul Agrawal, MDMSc, Andrea Corbacioglu, PhD, Daniela Weber, Silke Kapp-Schwoerer, MD, Verena I. Gaidzik, MD, Nikolaus Jahn, MD, Thomas Schroeder, MD, Mohammad Wattad, MD, Michael Lübbert, Elisabeth Koller, MD, Thomas Kindler, MD, Katharina Götze, Mark Ringhoffer, MD, Jörg Westermann, MD, Walter Fiedler, MD, Heinz A. Horst, MD, Richard Greil, MD, Roland Schroers, Karin Mayer, MD, Thomas Heinicke, MD, Jürgen Krauter, MD, Richard F. Schlenk, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD, Lars Bullinger, Peter Paschka, MD, Hartmut Döhner, MD, Konstanze Döhner
Journal: Blood
Blood (2019) 134 (Supplement_1): 2740.
https://doi.org/10.1182/blood-2019-125584
Published: 2019
Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Gail J. Roboz, MD, Hartmut Döhner, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw Jedrzejczak, MD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Jean-Pierre Issa, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2591.
https://doi.org/10.1182/blood-2019-127253
Published: 2019
Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Jean-Pierre Issa, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Pierre Fenaux, MD PhD, Gail J. Roboz, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4235.
https://doi.org/10.1182/blood-2019-129614
Published: 2019